[
    [
        {
            "time": "2023-10-05",
            "original_text": "Medicare Coverage for Libre 2 Boosts Abbott's CGM Prospects",
            "features": {
                "keywords": [
                    "Medicare",
                    "Coverage",
                    "Libre 2",
                    "Abbott",
                    "CGM"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Medicare Coverage for Libre 2 Boosts Abbott's CGM Prospects",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Abbott Announces Start of Trial to Evaluate the New Esprit™ BTK Drug-Eluting Resorbable Scaffold",
            "features": {
                "keywords": [
                    "Abbott",
                    "Trial",
                    "Esprit™",
                    "BTK",
                    "Drug-Eluting",
                    "Resorbable",
                    "Scaffold"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Abbott Announces Start of Trial to Evaluate the New Esprit™ BTK Drug-Eluting Resorbable Scaffold",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Fulgent Shares Up 10% On COVID-19 Testing Deal For New York Schools",
            "features": {
                "keywords": [
                    "Fulgent",
                    "Shares",
                    "Up",
                    "COVID-19",
                    "Testing",
                    "Deal",
                    "New York",
                    "Schools"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech",
                    "education"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Fulgent Shares Up 10% On COVID-19 Testing Deal For New York Schools",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]